Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Master Thesis FINAL - Andrew Muir.pdf (709.92 KB)

ETD Abstract Container

Abstract Header

Investigating the chondroprotective efficacy of autologous bovine platelet-rich plasma in Staphylococcus aureus-induced in vitro septic arthritis model

Muir, Andrew Jacob Thomas
http://rave.ohiolink.edu/etdc/view?acc_num=osu1620931729706365

Abstract Details

2021, Master of Science, Ohio State University, Comparative and Veterinary Medicine.
Septic arthritis is an important cause of lameness in cattle. There are currently no antimicrobials labeled for treatment of septic arthritis in cattle in the United States. In addition to the well established anti-inflammatory and chondroanabolic properties of platelet-rich plasma (PRP), recent in-vitro experimental studies have also highlighted the immune-metabolic effects and antimicrobial properties of PRP when used alone, and in conjunction with antimicrobials. Given the regulatory restrictions associated with antimicrobial use in cattle, PRP is of potential therapeutic benefit to this common clinical problem. The objective of this study was to evaluate the chondroprotective effects of ampicillin/sulbactam (Amp-S), autogenous PRP alone (PRP) or combined with Amp-S (PRP+Amp-S) in an explant model of bovine Staphylococcus aureus induced septic arthritis. Autogenous PRP was prepared prior to euthanizing 6 cows. Articular cartilage explants were collected from stifle joints and incubated in synovial fluid with 1 x 105 CFU/mL S. aureus ATCC 25923. Cartilage explants were incubated with S. aureus infected synovial fluid alone (S. aureus control), or S. aureus infected synovial fluid with treatments PRP (25% culture medium volume), Amp-S (2 mg/mL Unasyn™), or PRP+Amp-S for 24 hours. Explant chondrocyte viability, metabolic activity and GAG content were measured via live-dead assay/confocal microscopy, Alamar blue assay and DMMB assay, respectively. Data was analyzed with one-way ANOVA (p≤0.05). Cartilage explants inoculated with S. aureus (control) resulted in 64±10.5% dead cells. Treatment PRP (26±2.8%), Amp-S (25±10.6%) and PRP+Amp-S (22±4%) significantly decreased cell death. There was no significant difference in explant cell death and metabolic activity among the treatments. These results indicate that PRP, Amp-S, and PRP+Amp-S mitigated S. aureus-induced chondrocyte death in this in-vitro explant model of bovine septic arthritis. This data serves as a foundation for further in-vivo evaluation.
Sushmitha Durgam, BVSc, MS, PhD (Advisor)
Andrew Niehaus, DVM, MS (Advisor)
Dubraska Diaz-Campos, DVM, PhD (Committee Member)
Jeffrey Lakritz, DVM, PhD (Committee Member)
Joseph Lozier, DVM, MS (Committee Member)
57 p.
Osteopathic Medicine; Veterinary Services
Platelet-rich plasma; Autogenous bovine PRP; Septic arthritis; Explant model; Live-dead; Ampicillin-sulbactum

Recommended Citations

Citations

  • Muir, A. J. T. (2021). Investigating the chondroprotective efficacy of autologous bovine platelet-rich plasma in Staphylococcus aureus-induced in vitro septic arthritis model [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1620931729706365

    APA Style (7th edition)

  • Muir, Andrew. Investigating the chondroprotective efficacy of autologous bovine platelet-rich plasma in Staphylococcus aureus-induced in vitro septic arthritis model. 2021. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1620931729706365.

    MLA Style (8th edition)

  • Muir, Andrew. "Investigating the chondroprotective efficacy of autologous bovine platelet-rich plasma in Staphylococcus aureus-induced in vitro septic arthritis model." Master's thesis, Ohio State University, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=osu1620931729706365

    Chicago Manual of Style (17th edition)

osu1620931729706365
79
© 2021, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.